AR050643A1 - Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo - Google Patents
Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activoInfo
- Publication number
- AR050643A1 AR050643A1 ARP050103795A ARP050103795A AR050643A1 AR 050643 A1 AR050643 A1 AR 050643A1 AR P050103795 A ARP050103795 A AR P050103795A AR P050103795 A ARP050103795 A AR P050103795A AR 050643 A1 AR050643 A1 AR 050643A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituents
- diseases
- group
- heterocyclic group
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Los compuestos representados por la formula (1) tienenactividad antagonista contre CCR5, de modo que son utiles para la prevencion y/o tratamiento de enfermedades relacionadas con CCR5, por ejemplo, diversasd enfermedades inflamatorias (asma, nefritis, nefropatía, hepatitis, artritis, artritis reumatoidea, rinitis, conjuntivitis, enfermedad intestinal inflamatoria tal como colitis ulcerativa etc.), enfermedades inmunologicas (enfermedades autoinmunes, rechazo en transpalnte de organos (rechazo de injerto de organo solido, rechaazo de injerto de células de islas pancreáticas en terapia para diabetes, enfermedad de injerto versus huésped etc.), inmunosupresion, soriasis, esclerosis multiple, etc.) enfermedades infecciosas (infeccion con el virus de inmunodeficiencia humana, síndrome de inumunodeficiencia adquirida, infeccion con RSV, etc.), enfermedades alérgicas (dermatitis atopica, urticaria, aspergilosis broncopulmonar alérgica, gastroenteritis eosinofila alérgica, etc.), enfermedades cardiovasculares (arteriosclerosis, lesion por reperfusion isquémica, etc.), síndrome de insuficiencia rspiratoria aguda, infeccion bacteriana acompanante de choque, diabetes, metástasis cancerígena y enfermedades similares. Reivindicacion 1: Un compuesto representado por la formula (1) en dodne R1 representa (1) -N(R1A)SO2-R1B, (2) -SO2NR1CR1D, (3) -COOR1E, (4) -OR1F, (5) -S(O)mR1G, (6) -CONR1HR1J, (7) -NR1KCOR1L, o (8) ciano, en donde m es 0, 1 o 2; R1A, R1B, R1C, R1D, R1E, R1F, R1G, R1H, R1J, R1K y R1L cada uno independientemente representa un átomo de H, un grupo hidrocarburo el cual puede tener un sustituyente o más sustituyentes, o un grupo heterocíclico de 3 a 15 miembros el cual puede tener uno o más sustituyentes, y en donde R1C y R1D o R1H y R1J pueden formar un grupo heterocíclico que contiene N el cual puede tener uno o más sustituyentes junto con un átomo de N al cual se unen; X e Y cada uno independientemente representa un enlace o un espaciador que contiene 1 a 3 'tomos como una cadena principal; el anillo A y el anillo B, los cuales son iguales o diferentes, cada uno representa un grupo carbocíclico o grupo heterocíclico de 3 a 15 miembros el cual puede tener uno o más sustituyentes; el anillo D es un grupo heterocíclico que contiene N de 3 a 15 miembros el cual puede tener uno o más sustituyentes; R2 es (1) un átomo de H; (2) un grupo hidrocarburo el cual puede tener uno o más sustituyentes, (3) un grupo ciano, (4) un grupo hidroxi el cual puede estar protegido, (5) un grupo amino el cual puede tener uno o más sustituyentes, (6) un grupo oxo, (7) un grupo heterocíclico de 3 a 15 miembros el cual puede tener uno o más ustituyentes o (8) =N-OR6, en donde R5 representa un átomo de H o alquilo C1-4, su sal, su N-oxido o su solvato, o su profármaco.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004264855 | 2004-09-13 | ||
JP2005127359 | 2005-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050643A1 true AR050643A1 (es) | 2006-11-08 |
Family
ID=36060170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103795A AR050643A1 (es) | 2004-09-13 | 2005-09-12 | Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo |
Country Status (20)
Country | Link |
---|---|
US (3) | US8143404B2 (es) |
EP (2) | EP1790637B1 (es) |
JP (1) | JP4894518B2 (es) |
KR (1) | KR101231466B1 (es) |
CN (1) | CN101775013A (es) |
AR (1) | AR050643A1 (es) |
AU (1) | AU2005283326B2 (es) |
BR (1) | BRPI0515164A (es) |
CA (1) | CA2579501C (es) |
ES (1) | ES2457041T3 (es) |
IL (1) | IL181783A (es) |
MA (1) | MA28921B1 (es) |
MX (1) | MX2007002886A (es) |
NO (1) | NO20071342L (es) |
NZ (1) | NZ553696A (es) |
PE (2) | PE20060598A1 (es) |
RU (1) | RU2409565C2 (es) |
SG (1) | SG146673A1 (es) |
TW (1) | TWI400232B (es) |
WO (1) | WO2006030925A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0408332A (pt) | 2003-03-14 | 2006-03-21 | Ono Pharmaceutical Co | derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo |
EP1718624B1 (en) * | 2004-02-18 | 2009-03-25 | AstraZeneca AB | Benzamide derivatives and their use as glucokinase activating agents |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
MX2007002886A (es) | 2004-09-13 | 2007-05-16 | Ono Pharmaceutical Co | Derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo. |
CA2614746C (en) * | 2005-07-09 | 2011-05-10 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
CN101309690A (zh) * | 2005-08-16 | 2008-11-19 | 阿诺麦德股份有限公司 | 趋化因子受体结合化合物 |
KR20090008217A (ko) * | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
PT2018380E (pt) | 2006-05-19 | 2012-01-17 | Abbott Lab | Derivados de alcanos azabicíclicos substituídos com biciclo-heterociclo fundidos activos no cns |
TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
CL2007003061A1 (es) | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
WO2009058921A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
WO2009058919A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
DK2336125T3 (da) | 2008-04-11 | 2013-04-08 | Janssen Pharmaceutica Nv | Thiazolopyridin-2-yloxy-phenyl- og thioazolopyrazin-2-yloxy-phenyl-aminer som modulatorer af leukotrien-A4-hydrolase |
JP5600104B2 (ja) | 2008-08-01 | 2014-10-01 | ベンティアールエックス ファーマシューティカルズ, インコーポレイテッド | Toll様受容体アゴニスト処方物およびその使用 |
EP2324028A2 (en) | 2008-08-04 | 2011-05-25 | AstraZeneca AB | Therapeutic agents 414 |
JP5827123B2 (ja) * | 2008-09-16 | 2015-12-02 | ウェルズ ファーゴ バンク ナショナル アソシエイション | 乱用の可能性が低いpeg化オピオイド |
AU2009313392B2 (en) | 2008-11-06 | 2016-05-05 | Array Biopharma, Inc. | Methods of synthesis of benzazepine derivatives |
PL2385938T3 (pl) | 2009-01-12 | 2015-07-31 | Pfizer Ltd | Pochodne sulfonamidu |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
EP2430019B1 (en) | 2009-05-14 | 2013-09-18 | Janssen Pharmaceutica, N.V. | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
RU2016125705A (ru) | 2009-08-18 | 2018-12-04 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов |
CN102781933B (zh) * | 2009-08-18 | 2016-01-20 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
HUE029420T2 (en) | 2012-03-13 | 2017-02-28 | Respivert Ltd | Crystalline PI3 kinase inhibitors |
JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
EP3719019B1 (en) * | 2013-05-27 | 2022-01-19 | F. Hoffmann-La Roche AG | New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗rsv活性之吡唑并嘧啶 |
MX2020008061A (es) | 2018-01-31 | 2020-09-09 | Janssen Sciences Ireland Unlimited Co | Pirazolopirimidinas sustituidas con cicloalquilo que tienen actividad contra vrs. |
ES2957316T3 (es) | 2018-04-23 | 2024-01-17 | Janssen Sciences Ireland Unlimited Co | Compuestos heteroaromáticos que tienen actividad contra VSR |
KR20210106447A (ko) | 2018-11-22 | 2021-08-30 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 효능제 및 그의 용도 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
TWI834791B (zh) * | 2018-12-28 | 2024-03-11 | 日商田邊三菱製藥股份有限公司 | 吡咯啶化合物的結晶 |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1063744A (en) * | 1964-05-25 | 1967-03-30 | American Cyanamid Co | 4-substituted-4'-tertiary aminoalkoxy biphenyls |
US5169855A (en) | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
IL118469A (en) | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
IL125859A0 (en) | 1996-03-28 | 1999-04-11 | Glaxo Group Ltd | Pyrrolopyrrolone derivatives useful as inhibitors of neutrophil elastase |
AU5803398A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
DK0946545T3 (da) | 1996-12-19 | 2001-11-19 | Aventis Pharma Inc | Nye carboxysubstituerede cykliske carboxamidderivater |
ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
WO1999018077A1 (fr) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Derives de pyridine condenses |
AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
JP4321737B2 (ja) | 1997-12-17 | 2009-08-26 | 塩野義製薬株式会社 | 新規ピリジン化合物 |
KR20010032841A (ko) | 1997-12-19 | 2001-04-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 아닐리드 유도체를 함유하는 ccr5 길항용 약학 조성물 |
CA2319781A1 (en) | 1998-02-02 | 1999-08-05 | Liping Wang | Cyclic amine modulators of chemokine receptor activity |
GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
CA2329821A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
EP1076557A1 (en) | 1998-04-27 | 2001-02-21 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000006085A2 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Compounds and methods |
TR200100267T2 (tr) | 1998-07-28 | 2001-09-21 | Smithkline Beecham Corporation | İkameli anilid bileşimleri ve yöntemler. |
EP1100495A4 (en) | 1998-07-28 | 2002-09-25 | Smithkline Beecham Corp | PROPENAMIDES AS CCR5 MODULATORS |
AU5301599A (en) * | 1998-08-20 | 2000-03-14 | Takeda Chemical Industries Ltd. | Quaternary ammonium salts and their use |
AU6123099A (en) | 1998-10-15 | 2000-05-01 | Takeda Chemical Industries Ltd. | Process for the preparation of amine derivatives |
WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
EP1131291B1 (en) | 1998-11-17 | 2004-10-20 | F. Hoffmann-La Roche Ag | 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
WO2000031032A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives-ccr-3 receptor antagonists |
ATE386720T1 (de) | 1998-11-20 | 2008-03-15 | Hoffmann La Roche | Piperidin ccr-3 rezeptor-hemmer |
WO2000034278A1 (fr) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif |
US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
DE69926919D1 (de) | 1998-12-18 | 2005-09-29 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
EP1140086A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
AU2482100A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
WO2000035454A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
CA2347912A1 (en) | 1998-12-18 | 2000-06-22 | Soo S. Ko | Heterocyclic piperidines as modulators of chemokine receptor activity |
US6441001B1 (en) | 1998-12-18 | 2002-08-27 | Bristol-Myers Squibb Pharma Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
EP1140896A1 (en) | 1998-12-21 | 2001-10-10 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
EP1140072B1 (en) | 1998-12-30 | 2004-04-14 | Smithkline Beecham Corporation | Compounds and methods |
KR20010086166A (ko) | 1999-01-13 | 2001-09-08 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 케모카인 수용체 조절제로서의 관능화된 헤테로시클 |
WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000042852A1 (en) | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Compounds and methods |
GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
JP2000309598A (ja) | 1999-02-25 | 2000-11-07 | Takeda Chem Ind Ltd | 多剤結合型新規化合物、その製造法および用途 |
WO2000051609A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
US6372764B1 (en) | 1999-03-02 | 2002-04-16 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6362201B1 (en) | 1999-03-02 | 2002-03-26 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
AU3386700A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
US6506790B1 (en) | 1999-03-10 | 2003-01-14 | Smithkline Beecham Corporation | Compounds and methods |
AU2942000A (en) | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
ES2265923T3 (es) | 1999-03-24 | 2007-03-01 | Anormed Inc. | Compuestos heterociclicos que se unen a receptores de quimiocinas. |
CA2361366A1 (en) | 1999-03-26 | 2000-10-05 | Nicholas Kindon | Novel compounds |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6265434B1 (en) | 1999-04-06 | 2001-07-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6498161B1 (en) | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
EP1180513A4 (en) | 1999-04-28 | 2002-07-10 | Takeda Chemical Industries Ltd | CYCLIC AMID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND USE THEREOF |
EP1189609A4 (en) | 1999-05-03 | 2002-10-30 | Smithkline Beecham Corp | CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA |
SK286968B6 (sk) * | 1999-05-04 | 2009-08-06 | Schering Corporation | Piperidín-piperidinyl ako CCR5 antagonista, farmaceutický prostriedok s jeho obsahom a jeho použitie |
SK286641B6 (sk) | 1999-05-04 | 2009-03-05 | Schering Corporation | Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie |
EP1175224B1 (en) | 1999-05-04 | 2005-02-23 | Schering Corporation | Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6627651B1 (en) | 1999-05-07 | 2003-09-30 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
WO2000069815A1 (en) | 1999-05-13 | 2000-11-23 | Teijin Limited | Ureido-substituted cyclic amine derivatives and their use as drug |
NZ515374A (en) | 1999-05-18 | 2004-09-24 | Teijin Ltd | Remedies or prophylactics for diseases in association with chemokines |
WO2000073327A1 (en) | 1999-05-27 | 2000-12-07 | Celltek Biotechnologies Inc. | Chemokine receptor ccr3 antagonists |
US6165261A (en) | 1999-06-10 | 2000-12-26 | Ergon, Inc. | Water-resistant gypsum composition |
DE60027011T2 (de) | 1999-07-28 | 2006-12-07 | Kirin Beer K.K. | Harnstoffderivate als CCR-3 Rezeptor-Inhibitoren |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
WO2001016114A2 (en) | 1999-08-27 | 2001-03-08 | Chemocentryx, Inc. | Heterocyclic compounds and methods for modulating cxcr3 function |
FR2798367B1 (fr) * | 1999-09-15 | 2001-11-23 | Valois Sa | Joint de soupape pour valve doseuse |
WO2001040227A1 (fr) | 1999-12-03 | 2001-06-07 | Ono Pharmaceutical Co., Ltd. | Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
US6894063B2 (en) | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
CA2422013A1 (en) | 2000-09-14 | 2002-03-21 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
CA2431553A1 (en) | 2000-12-11 | 2002-10-24 | Tularik Inc. | Cxcr3 antagonists |
GB0100102D0 (en) | 2001-01-03 | 2001-02-14 | Syngenta Participations Ag | Organic compounds |
EP1370546A2 (en) | 2001-03-16 | 2003-12-17 | Abbott Laboratories | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
IL157819A0 (en) | 2001-03-19 | 2004-03-28 | Ono Pharmaceutical Co | Triazaspiro [5.5] undecane dericatives and drugs containing the same as the active ingredient |
ATE299139T1 (de) * | 2001-03-29 | 2005-07-15 | Schering Corp | Ccr5 antagonisten verwendbar für die behandlung von aids |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
MXPA03009000A (es) * | 2001-04-13 | 2004-02-12 | Boehringer Ingelheim Pharma | Compuestos benzo-fusionados 1,4-disustituidos. |
US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
US6495569B1 (en) | 2001-04-19 | 2002-12-17 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
US6720321B2 (en) * | 2001-06-05 | 2004-04-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
YU94103A (sh) | 2001-06-20 | 2006-03-03 | Pfizer Products Inc. | Novi derivati sulfonske kiseline |
US6867221B2 (en) * | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
WO2003037271A2 (en) | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
RU2004117907A (ru) * | 2001-11-14 | 2006-01-10 | Шеринг Корпорейшн (US) | Лиганды каннабиноидных рецепторов |
TW200302717A (en) | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
AU2003231872A1 (en) | 2002-06-03 | 2003-12-19 | Smithkline Beecham Corporation | Imidazolium cxcr3 inhibitors |
JPWO2003104230A1 (ja) | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
KR20050057408A (ko) | 2002-09-18 | 2005-06-16 | 오노 야꾸힝 고교 가부시키가이샤 | 트리아자스피로[5.5]운데칸 유도체 및 이를 유효 성분으로하는 약제 |
JP2006511500A (ja) * | 2002-10-30 | 2006-04-06 | メルク エンド カムパニー インコーポレーテッド | γ−アミノアミド系のケモカイン受容体活性調節剤 |
CA2504941C (en) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
WO2004046110A1 (ja) | 2002-11-15 | 2004-06-03 | Yamanouchi Pharmaceutical Co., Ltd. | メラニン凝集ホルモン受容体拮抗剤 |
JP4666256B2 (ja) * | 2002-12-10 | 2011-04-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
JP2004256531A (ja) | 2003-02-07 | 2004-09-16 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および用途 |
GB0305426D0 (en) | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
BRPI0408332A (pt) | 2003-03-14 | 2006-03-21 | Ono Pharmaceutical Co | derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo |
JP4616831B2 (ja) | 2003-04-24 | 2011-01-19 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
US7732442B2 (en) * | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
MX2007002886A (es) | 2004-09-13 | 2007-05-16 | Ono Pharmaceutical Co | Derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo. |
JP2007063268A (ja) | 2005-08-05 | 2007-03-15 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
CN101309690A (zh) | 2005-08-16 | 2008-11-19 | 阿诺麦德股份有限公司 | 趋化因子受体结合化合物 |
KR20090008217A (ko) | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
-
2005
- 2005-09-12 MX MX2007002886A patent/MX2007002886A/es active IP Right Grant
- 2005-09-12 NZ NZ553696A patent/NZ553696A/en not_active IP Right Cessation
- 2005-09-12 JP JP2006535240A patent/JP4894518B2/ja not_active Expired - Fee Related
- 2005-09-12 RU RU2007113814/04A patent/RU2409565C2/ru not_active IP Right Cessation
- 2005-09-12 KR KR1020077008318A patent/KR101231466B1/ko not_active IP Right Cessation
- 2005-09-12 EP EP05785808.6A patent/EP1790637B1/en not_active Not-in-force
- 2005-09-12 US US11/662,639 patent/US8143404B2/en not_active Expired - Fee Related
- 2005-09-12 AU AU2005283326A patent/AU2005283326B2/en not_active Ceased
- 2005-09-12 BR BRPI0515164-3A patent/BRPI0515164A/pt not_active IP Right Cessation
- 2005-09-12 WO PCT/JP2005/017209 patent/WO2006030925A1/ja active Application Filing
- 2005-09-12 PE PE2005001056A patent/PE20060598A1/es not_active Application Discontinuation
- 2005-09-12 EP EP12186689A patent/EP2546234A1/en not_active Withdrawn
- 2005-09-12 SG SG200807030-2A patent/SG146673A1/en unknown
- 2005-09-12 CA CA2579501A patent/CA2579501C/en not_active Expired - Fee Related
- 2005-09-12 PE PE2008001407A patent/PE20090123A1/es not_active Application Discontinuation
- 2005-09-12 AR ARP050103795A patent/AR050643A1/es not_active Application Discontinuation
- 2005-09-12 TW TW094131265A patent/TWI400232B/zh not_active IP Right Cessation
- 2005-09-12 CN CN201010126265A patent/CN101775013A/zh active Pending
- 2005-09-12 ES ES05785808.6T patent/ES2457041T3/es active Active
-
2007
- 2007-03-07 IL IL181783A patent/IL181783A/en not_active IP Right Cessation
- 2007-03-12 NO NO20071342A patent/NO20071342L/no not_active Application Discontinuation
- 2007-04-06 MA MA29806A patent/MA28921B1/fr unknown
-
2011
- 2011-01-28 US US13/016,849 patent/US8410276B2/en not_active Expired - Fee Related
-
2012
- 2012-11-21 US US13/682,784 patent/US8604207B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050643A1 (es) | Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo | |
EA200870344A1 (ru) | Азотсодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента | |
AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
NO20054244L (no) | Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel | |
ES2630705T3 (es) | Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas | |
Medapi et al. | Design and synthesis of novel quinoline–aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors | |
CO2017001603A2 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
NO20065694L (no) | Indolderivat med piperidinring | |
AR082519A1 (es) | Fenilamidinas que tienen alta actividad fungicida, y su utilizacion | |
NO20072688L (no) | Aminpyridinderivat med aurora A-selektiv inhiberende virkning | |
NO20075768L (no) | Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90 | |
CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
EP1541574A4 (en) | TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT | |
PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
NO20085140L (no) | Nye indazolderivater som har spiro ringstruktur i sidekjede | |
PE20061078A1 (es) | Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4) | |
PE20090293A1 (es) | COMPUESTO DERIVADO DE 3-(IMIDAZOLIL)-PIRAZOLO[3,4-b]PIRIDINAS, PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
AR070454A1 (es) | Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden | |
AU2013302319A1 (en) | VEGFR3 inhibitors | |
ECSP088378A (es) | Derivados de piperazina útiles como antagonistas de ccr5 | |
UA102073C2 (ru) | Улучшение свойств органических соединений или характеристик, связанных с органическими соединениями | |
NO20091779L (no) | Nye indolforbindelser en prosess for deres fremstilling og farmasoytiske sammensetninger som inneholder dem | |
AR077898A1 (es) | Metilpirrolopirimidincarboxamidas | |
Kumar et al. | Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |